• GA/PPC-Modified Lipid Nanoparticles for siRNA Delivery in Li

  2026-05-20

  This study introduces a novel lipid nanoparticle system incorporating glycyrrhizic acid (GA) and polyene phosphatidylcholine (PPC) to enhance the delivery of p65 siRNA, resulting in improved therapeutic efficacy against acute liver injury. The approach demonstrates reduced cytotoxicity, improved cellular uptake, and increased gene silencing, offering a promising direction for nucleic acid-based therapies targeting inflammation.

• Ibrexafungerp and Caspofungin: Efficacy Against Resistant Ca

  2026-05-20

  Wiederhold et al. demonstrated that ibrexafungerp, an oral glucan synthase inhibitor, exhibits potent in vitro and in vivo activity against fluconazole-resistant Candida auris, even when therapy initiation is delayed. The study benchmarks ibrexafungerp’s efficacy alongside caspofungin, with significant implications for antifungal agent selection in resistant Candida research.

• Phenylmethanesulfonyl fluoride (PMSF) for Reliable Protein E

  2026-05-19

  This scenario-driven article explores common laboratory hurdles in protein extraction, Western blot sample preparation, and cell viability assays, and demonstrates how Phenylmethanesulfonyl fluoride (PMSF, SKU A2587) provides reproducible, data-backed solutions. Drawing on real experimental challenges, it guides biomedical researchers in selecting and applying PMSF to safeguard protein integrity and ensure high-quality, interpretable results.

• Lopinavir (ABT-378): Advanced Strategies for HIV and Cross-V

  2026-05-19

  Explore the unique efficacy of Lopinavir (ABT-378) in HIV protease inhibition, resistance mutation profiling, and emerging antiviral research. This article offers advanced, evidence-based protocols and cross-domain insights unavailable elsewhere.

• Topotecan HCl: Precision DNA Damage Modulation in Tumor Mode

  2026-05-18

  Explore how Topotecan HCl, a leading topoisomerase 1 inhibitor, enables precise modulation of DNA damage and apoptosis in advanced cancer research. This article uncovers unique, evidence-based assay insights and bridges mechanistic knowledge with practical protocol optimization.

• SOAT1 Inhibition Restores Lipophagy in PHMG-Induced Lung Fib

  2026-05-18

  This study uncovers sterol O-acyltransferase 1 (SOAT1) as a critical driver of foam cell formation and fibrosis in lungs exposed to polyhexamethylene guanidine (PHMG). By demonstrating that SOAT1 inhibition restores lipophagy and mitigates pro-fibrotic signaling, the research highlights a promising therapeutic target for toxin-induced and potentially broader fibrotic lung diseases.

• ARCA Cy3 EGFP mRNA (5-moUTP): Benchmarks for Fluorescent mRN

  2026-05-17

  ARCA Cy3 EGFP mRNA (5-moUTP) is a 5-methoxyuridine modified, Cy3-labeled mRNA optimized for direct visualization and translational efficiency in mammalian cell studies. This reagent enables precise, real-time tracking of mRNA uptake and expression. It offers superior immune evasion and stability over unmodified mRNA reagents.

• WM-8014: Precision KAT6A Inhibitor Workflows in Cancer Biolo

  2026-05-16

  WM-8014 empowers advanced, selective modulation of epigenetic pathways via KAT6A inhibition—enabling robust oncogene-induced senescence studies without general cytotoxicity. This guide provides actionable protocols and troubleshooting tips, translating breakthrough findings into reproducible, high-confidence workflows for cancer biology research.

• Applied Insights with the Dual Luciferase Reporter Gene Syst

  2026-05-15

  Harness the Dual Luciferase Reporter Gene System for precision gene expression regulation studies, leveraging streamlined workflows and robust normalization. This article translates recent advances in plant transcriptional regulation into actionable protocols for high-throughput mammalian assays—optimizing sensitivity, reliability, and reproducibility.

• OTUD3 Stabilizes SLC7A11 to Drive Sunitinib Resistance in cc

  2026-05-15

  This study delineates how OTUD3 overexpression in clear cell renal cell carcinoma (ccRCC) promotes resistance to sunitinib by stabilizing the cystine transporter SLC7A11. By suppressing ferroptosis through redox regulation, OTUD3 renders tumor cells less sensitive to lipid peroxidation-driven cell death, highlighting a potential therapeutic target to overcome drug resistance.

• Cefodizime: Mechanistic Insights Into a Third-Generation Cep

  2026-05-14

  Explore the advanced mechanism and research applications of Cefodizime, a third-generation cephalosporin antibiotic. This article delivers a deep dive into its molecular action, immunomodulatory properties, and evidence-based assay parameters, setting it apart from prior content.

• CCK-8s Drives ANP Secretion via NOX4–PGC-1α–PPAR Signaling i

  2026-05-14

  This study reveals that sulfated cholecystokinin octapeptide (CCK-8s) directly stimulates atrial natriuretic peptide (ANP) secretion through a defined NOX4–PGC-1α–PPARα/PPARγ pathway in isolated beating rat atria. These findings clarify the mechanistic interplay between cardiac neurohormonal signaling, oxidative processes, and peptide hormone release, with implications for cardiovascular and inflammation research.

• Entecavir (BMS200475): Resistance Risk, Clinical Impact, and

  2026-05-13

  Explore Entecavir (BMS200475) as a potent HBV DNA polymerase inhibitor, with unique focus on resistance dynamics, clinical impact, and protocol optimization. This article delivers deeper analysis for chronic hepatitis B research and therapy.

• PDHA1 Acetylation Regulates Cuproptosis and Drug Resistance

  2026-05-13

  This study identifies acetylation-dependent signaling through PDHA1 as a key suppressor of cuproptosis, enabling resistance to anti-androgen therapy in castration-resistant prostate cancer (CRPC). By mechanistically linking metabolic and epigenetic reprogramming to therapeutic response, the findings highlight PDHA1 as a promising target for restoring cell death sensitivity in advanced prostate cancer.

• HyperScribe T7 High Yield RNA Synthesis Kit in lncRNA Therap

  2026-05-12

  Explore how the HyperScribe T7 High Yield RNA Synthesis Kit enables advanced RNA synthesis for lncRNA-targeted cancer therapeutics. This article uniquely connects the kit’s high-yield capabilities with practical design of RNA-based interventions against metastatic disease.

15395 records 1/1027 page Next 12345 下5页 Last page